A pilot study of the clinical efficacy of platelet-rich plasma (PRP) for the treatment of endocrine therapy-induced alopecia (EIA) and permanent chemotherapy-induced alopecia (pCIA) in breast cancer patients.

富血小板血浆（PRP）治疗乳腺癌患者内分泌治疗引起的脱发（EIA）和永久性化疗引起的脱发（pCIA）临床疗效的初步研究。

• 批准号: 437123420
• 负责人: Dr. Christian Menzer
• 金额: --
• 依托单位: Division of Subspecialty Medicine
• 依托单位国家: 德国
• 项目类别: Research Fellowships
• 财政年份: 2020
• 资助国家: 德国
• 起止时间: 2019-12-31 至 2022-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/437123420?language=en
• 关键词: pilot; study; clinical; efficacy; platelet

Breast cancer is the most common cancer among women, with over 2 million new cases diagnosed worldwide in 2018. Modern therapies, consisting of chemotherapy and anti-hormonal therapy, are successfully used with a survival rate of greater than 80% in early stages. These anti-hormonal (endocrine) therapies are now recommended for as long as 5-10 years. Therefore, long-term side effects such as hair loss (alopecia) substantially compromise the quality of life in these patients. 8% of patients discontinue hormone therapy because of hair loss. Up to 25% suffer from hair loss because of the reduction of female hormones caused by the cancer treatment. Also, up to two thirds of patients treated with chemotherapy never fully grow back their hair afterwards. This can be a psychologically devastating event.Available treatments include minoxidil, a topical therapy that increases blood supply to the scalp, which has shown some improvement in hormone therapy-related hair loss, and the blood pressure medication spironolactone. There is, however, a need for further therapies for women who do not respond to minoxidil or spironolactone.Platelet Rich Plasma (PRP) was first used in orthopedic sports injuries to speed up recovery but has been increasingly used in dermatology for wound support, facial rejuvenation, and also hair loss. Platelets (thrombocytes) are a component of the blood that contains a high concentration of proteins with anti-inflammatory and growth-stimulating effects. PRP is obtained after blood centrifugation from the patient.In women with postmenopausal hair loss, PRP injections have shown a significant change in hair density and thickness even if the women had already received treatment with minoxidil or systemic therapy. Hair loss due to menopause resembles the cause of hair loss due to anti-hormonal therapy in cancer patients and suggests that PRP may be a suitable treatment for breast cancer patients suffering from this condition.In this pilot study, we want to treat breast cancer patients, who are experiencing hormone therapy- (EIA) and chemotherapy-related hair loss (pCIA), with PRP. 14 patients of each entity, EIA and pCIA, will be included. The patients will receive PRP injections on one half of their scalp whereas the other half of the scalp will not be treated, to serve as a study control. PRP is injected to the same half of the scalp once every 4 weeks for 12 weeks in a grid-like pattern. Treatment efficacy will be assessed at weeks 12 and 24 after the start of PRP. The effect on the quality of life will also be assessed. After 24 weeks, patients can cross over to a PRP treatment of the untreated side of their scalp if a benefit is seen.

乳腺癌是女性最常见的癌症，2018年在全球范围内诊断出了200万例新病例。现代疗法包括化学疗法和抗激素疗法，在早期阶段的存活率大于80％。现在，建议使用这些抗激素（内分泌）疗法长达5 - 10年。因此，诸如脱发（脱发）之类的长期副作用实质上损害了这些患者的生活质量。由于脱发，有8％的患者停止激素治疗。由于癌症治疗引起的女性激素减少，多达25％的人患有脱发。同样，多达三分之二的接受化学疗法治疗的患者之后从未完全恢复头发。这可能是一个在心理上是毁灭性的事件。可利用的疗法包括米诺地尔，米诺地尔是一种局部疗法，可增加头皮血液供应，这表明与激素治疗相关的脱发相关的脱发有所改善，以及血压药物螺内乳突。但是，对于对米诺地尔或螺内酯反应不反应的女性，需要进一步的疗法。Platelet富血浆（PRP）首次用于骨科运动损伤中，以加快恢复的速度，但越来越多地用于皮肤病学用于伤口支撑，面部再生和脱发。血小板（血小板）是血液的一个组成部分，其中含有高浓度的具有抗炎和生长刺激作用的蛋白质。在绝经后脱发后，PRP注射的女性在患者的血液离心后获得PRP，即使女性已经接受了米诺地尔或全身治疗的治疗，头发密度和厚度也有显着变化。 由于更年期导致的脱发类似于癌症患者抗激素疗法引起的脱发原因，并表明PRP可能是患有这种疾病的乳腺癌患者的合适疗法。在这项试验研究中，我们想治疗正在接受激素疗法的乳腺癌患者（EIA）（EIA）（EIA）和与化学疗法相关的脱发（PCIA）（PCIA）。每个实体，EIA和PCIA的14例患者将包括在内。患者将在其头皮的一半接受PRP注射，而头皮的另一半将被治疗为研究控制。 PRP以网格样模式注入每4周的头皮的同一半，持续12周。 PRP开始后的第12和24周将评估治疗疗效。还将评估对生活质量的影响。 24周后，如果看到益处，患者可以跨越头皮未处理的一侧的PRP治疗。